Suppressor of Cytokine Signaling (SOCS) Genes Are Downregulated in Breast Cancer

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2018 Nov 21

PMID 30453988

Citations 26

Authors

Soudeh Ghafouri-Fard

Vahid Kholghi Oskooei

Iman Azari

Mohammad Taheri

Affiliations

Soon will be listed here.

Abstract

Background: The suppressor of cytokine signaling (SOCS) family of proteins are inhibitors of the cytokine-activated Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. We aimed at evaluation of expression of SOCS genes in breast cancer.

Methods: We evaluated expression of SOCS1-3 and SOCS5 genes in breast cancer samples compared with the corresponding adjacent non-cancerous tissues (ANCTs).

Results: All assessed SOCS genes were significantly downregulated in tumoral tissues compared with ANCTs. SOCS1 and SOCS2 genes were significantly overexpressed in higher grade samples, but SOCS3 had the opposite trend. Significant correlations were found between expression levels of SOCS genes. The SOCS1 and SOCS2 expression levels had the best specificity and sensitivity values respectively for breast cancer diagnosis.

Conclusion: The current study provides further evidence for contribution of SOCS genes in breast cancer.

Citing Articles

The importance of SOCS1 - 1478 CA/del polymorphism and expression in breast cancer: a case-control study in the north of Iran.

Paeiz H, Salehi Z, Mashayekhi F, Saedi H, Mirzanejad L Breast Cancer Res Treat. 2023; 202(2):389-395.

PMID: 37526791 DOI: 10.1007/s10549-023-07070-3.

gene polymorphism is associated with downregulation of expression, suppressor of cytokine signaling-1 overexpression, and low probability of metastatic tumor at the time of breast cancer diagnosis.

Iranparast S, Tahmasebi-Birgani M, Motamedfar A, Amari A, Ghafourian M J Res Med Sci. 2023; 28:32.

PMID: 37213455 PMC: 10199376. DOI: 10.4103/jrms.jrms_960_21.

Breast Cancer: Circular RNAs Mediating Efficacy in Preclinical Models.

Weidle U, Hsia H, Brinkmann U Cancer Genomics Proteomics. 2023; 20(3):222-238.

PMID: 37093684 PMC: 10148070. DOI: 10.21873/cgp.20377.

Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2023; 20(2):117-131.

PMID: 36870692 PMC: 9989670. DOI: 10.21873/cgp.20368.

A zebrafish HCT116 xenograft model to predict anandamide outcomes on colorectal cancer.

Maradonna F, Fontana C, Sella F, Giommi C, Facchinello N, Rampazzo C Cell Death Dis. 2022; 13(12):1069.

PMID: 36564370 PMC: 9789132. DOI: 10.1038/s41419-022-05523-z.

References

Farabegoli F, Ceccarelli C, Santini D, Taffurelli M . Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005; 58(10):1046-50. PMC: 1770736. DOI: 10.1136/jcp.2004.024919. View

Sasi W, Jiang W, Sharma A, Mokbel K . Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 2010; 10:178. PMC: 2876081. DOI: 10.1186/1471-2407-10-178. View

Darnell J . Validating Stat3 in cancer therapy. Nat Med. 2005; 11(6):595-6. DOI: 10.1038/nm0605-595. View

Sutherland K, Lindeman G, Choong D, Wittlin S, Brentzell L, Phillips W . Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 2004; 23(46):7726-33. DOI: 10.1038/sj.onc.1207787. View

Rottapel R, Ilangumaran S, Neale C, La Rose J, Barber D, Dubreuil P . The tumor suppressor activity of SOCS-1. Oncogene. 2002; 21(28):4351-62. DOI: 10.1038/sj.onc.1205537. View

Yoshikawa H, Matsubara K, Qian G, Jackson P, Groopman J, Manning J . SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001; 28(1):29-35. DOI: 10.1038/ng0501-29. View

Lim E, Hong D, Park J, Joung Y, Darvin P, Kim S . Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways. PLoS One. 2012; 7(4):e33361. PMC: 3317666. DOI: 10.1371/journal.pone.0033361. View

Jiang M, Zhang W, Liu P, Yu W, Liu T, Yu J . Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment. Front Immunol. 2017; 8:70. PMC: 5296614. DOI: 10.3389/fimmu.2017.00070. View

Evans M, Yu C, Lohani A, Mahdi R, Liu X, Trzeciak A . Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene. 2006; 26(13):1941-8. DOI: 10.1038/sj.onc.1209993. View

10.

Kario E, Marmor M, Adamsky K, Citri A, Amit I, Amariglio N . Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem. 2004; 280(8):7038-48. DOI: 10.1074/jbc.M408575200. View

11.

Weniger M, Melzner I, Menz C, Wegener S, Bucur A, Dorsch K . Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006; 25(18):2679-84. DOI: 10.1038/sj.onc.1209151. View

12.

Barclay J, Anderson S, Waters M, Curlewis J . SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer. 2008; 124(8):1756-66. DOI: 10.1002/ijc.24172. View

13.

Cooney R . Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock. 2002; 17(2):83-90. DOI: 10.1097/00024382-200202000-00001. View

14.

Kim M, Kim M, Kim W, Kang M, Cacalano N, Kang S . Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One. 2015; 10(4):e0123133. PMC: 4388447. DOI: 10.1371/journal.pone.0123133. View

15.

Haffner M, Petridou B, Peyrat J, Revillion F, Muller-Holzner E, Daxenbichler G . Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer. 2007; 7:136. PMC: 1948006. DOI: 10.1186/1471-2407-7-136. View

16.

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi G, Ueno N . Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136(2):331-45. PMC: 3832208. DOI: 10.1007/s10549-012-2289-9. View

17.

Raccurt M, Tam S, Lau P, Mertani H, Lambert A, Garcia-Caballero T . Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer. 2003; 89(3):524-32. PMC: 2394374. DOI: 10.1038/sj.bjc.6601115. View

18.

Haan S, Wuller S, Kaczor J, Rolvering C, Nocker T, Behrmann I . SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009; 28(34):3069-80. DOI: 10.1038/onc.2009.155. View

19.

Smolkova B, Mego M, Kajabova V, Cierna Z, Danihel L, Sedlackova T . Expression of SOCS1 and CXCL12 Proteins in Primary Breast Cancer Are Associated with Presence of Circulating Tumor Cells in Peripheral Blood. Transl Oncol. 2016; 9(3):184-90. PMC: 4856862. DOI: 10.1016/j.tranon.2016.03.004. View

20.

Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A . SOCS, inflammation, and cancer. JAKSTAT. 2013; 2(3):e24053. PMC: 3772102. DOI: 10.4161/jkst.24053. View